A Phase 4 interventional study of Stiripentol in Pharmacoresistant Focal Epilepsies, sponsored by Biocodex. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2024-07-24.
Sponsored by Biocodex · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Epilepsies, Partial with a site in France — 11 open to participants now, 12 under way, 2 of them phase 3. Epilepsies, Partial · France.
Among the 40 studies in Epilepsies, Partial with a site in France, this one is the 25th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 4 in phase 4, and was the 34th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →11 of the 40 studies in Epilepsies, Partial with a site in France are open now. Recruiting first, the newest first:
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 6–50
University Hospital, Lille · Sites in France
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18–65
University Hospital, Tours · Sites in France
Ages 1–18
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 12 · Phase 4 4
First in 1998; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 157 across the 27 interventional studies, 102 across the 13 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 40 have an industry lead sponsor. The 10 most frequent:
Biocodex is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Biocodex has 1 study filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
4 of the studies in Epilepsies, Partial with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT02890641Fondation Ophtalmologique Adolphe de RothschildGenetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies | 2026-12 |
| NCT06466681University Hospital, LilleChanges in Attentional Control After a Focal Seizure. | 2027-03-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Epilepsies, Partial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The medical records of CRéER patients with the following criteria will be included in the retrospective part of the research by an investigator:
For which an information note indicating the possibility of opposing the processing of data has been provided.
Among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research:
Exclusion Criteria:
Patients with the following criteria will not be able to participate in the prospective part of the research:
Drug: Stiripentol
Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.
Age
Age of onset, nature of the first seizure and description of the type of the first seizure.
Time frame: through study completion, an average of 1 year
Previous antiepileptic treatments received
proportion of patients having received each antiepileptic treatment; for the treatments received, description of the reasons for stopping.
Time frame: through study completion, an average of 1 year
Surgery
proportion of patients having undergone epilepsy surgery.
Time frame: through study completion, an average of 1 year
Adjustment of carbamazepine treatment over the time
mean and median duration of treatment, mean and median daily dose received, dose change(s) during treatment...
Time frame: through study completion, an average of 1 year
Adjustment of stiripentol treatment over the time
mean and median duration of treatment, mean and median daily dose received, dose change(s) during treatment...
Time frame: through study completion, an average of 1 year
Adjustment of concomitant treatments over the time
continuation without change, change in dosage, discontinuation
Time frame: through study completion, an average of 1 year
monthly seizures over the time
description of the average number of monthly seizures since the last visit (total and by type of seizure)
Time frame: through study completion, an average of 1 year
status epilepticus in the past
proportion of patients who presented with status epilepticus
Time frame: through study completion, an average of 1 year
duration of the status epileticus over the time
duration of status epilepticus
Time frame: through study completion, an average of 1 year
emergency room consultation and/or hospitalization over the time
Proportion of patients requiring an emergency room consultation and/or hospitalized during the period preceding the visit.
Time frame: through study completion, an average of 1 year
emergency antiepileptic treatment over the time
Proportion of patients taking emergency antiepileptic treatment in the period before each visit
Time frame: through study completion, an average of 1 year
frequency of the status epileticus over the time
frequency of status epilepticus
Time frame: through study completion, an average of 1 year
Retention rate of the combination
The retention rate of the combination will correspond to the proportion of patients still receiving the combination (carbamazepine and stiripentol) at a given time.
Time frame: through study completion, an average of 1 year
Response to the combination
The rate of patients responding to the combination will be defined by the percentage of patients in whom a 50% reduction in visible seizures will be observed since the initiation of the carbamazepine and stiripentol combination. Will be estimated: oThe percentage of responder patients at the post-initiation visit of the combination (first follow-up visit after initiation of stiripentol) oThe percentage of responder patients during treatment regardless of the duration of treatment after which the response is obtained. oThe cumulative incidence of responder patients.
Time frame: through study completion, an average of 1 year
Tolerance of the combination.
Proportion of patients with Adverse Effects (AEs) related to the combination or to one of the treatments,
Time frame: through study completion, an average of 1 year
Frequency and nature of the adverse events over the time
Frequency and nature of the adverse events over the time
Time frame: through study completion, an average of 1 year
Abnormal biological parameters (NFS and liver)
proportion of patients with abnormal laboratory values (NFS and liver function) during
Time frame: through study completion, an average of 1 year
Maximum Concentration (Cmax) for stiripentol, carbamazepines and its metabolites
Cmax calculation
Time frame: through study completion, an average of 1 year
Area under the plasma concentration versus time curve (AUC) 0-8 for stiripentol, carbamazepines and its metabolites
AUC0-8 calculation
Time frame: through study completion, an average of 1 year
Area under the plasma concentration versus time curve (AUC) 0-24 for stiripentol, carbamazepines and its metabolites
AUC0-24 calculation
Time frame: through study completion, an average of 1 year
Time of Maximum (Tmax)concentration for stiripentol, carbamazepines and its metabolites
Tmax calculation
Time frame: through study completion, an average of 1 year
half-life (t1/2) for stiripentol, carbamazepines and its metabolites
t1/2 calculation
Time frame: through study completion, an average of 1 year
Pre-dose trough concentration (Ctrough) for stiripentol, carbamazepines and its metabolites
Ctrough calculation
Time frame: through study completion, an average of 1 year
Ran from Oct 2022 to primary completion in Jun 2024, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stiripentol
Biocodex